Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT001, a Novel Bispecific IL-4Ra/IL-31 Antibody: Results from the Single- and Multiple-Ascending Dose Portions of a Phase I Study in Healthy Volunteers and Patients with Atopic Dermatitis

BBT001 - Bambusa Therapeutics

https://eposters.aad.org/abstracts/75979

Peter Schrader; Hariz Hassan; Lisa Li; Wei Liang; Jingjing Jiang; Thang Ho; Shanshan Xu

Mar 12, 2026